High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?
Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Rece...
Gespeichert in:
| Veröffentlicht in: | Seminars in oncology 2001-08, Vol.28 (4), p.377-388 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 388 |
|---|---|
| container_issue | 4 |
| container_start_page | 377 |
| container_title | Seminars in oncology |
| container_volume | 28 |
| creator | Baynes, Roy D Dansey, Roger D Klein, Jared L Hamm, Caroline Campbell, Mark Abella, Esteban Peters, William P |
| description | Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field. |
| doi_str_mv | 10.1016/S0093-7754(01)90131-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71084755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093775401901319</els_id><sourcerecordid>71084755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c306t-ba6c6e740c65855aac52265bc481c14832f12a680bea884ba4dd5b7bd3be0f823</originalsourceid><addsrcrecordid>eNqFkMFu1DAQhi1ERZfCI4B8AcEhxePEsdNLhSqglSoVCThbE2fCGiVxsB2kvj1Jd0WPnEYz-mbm18fYKxDnIKD-8E2Ipiy0VtU7Ae8bASUUzRO2A1XKwmhhnrLdP-SUPU_plxAStJTP2ClA1RhTwo7Rtf-5L7qQiLs9jSHvKeJ8z3Hq-NpjDnPwlL3jKdPIHQ0DzxGnNA84Zcw-TLwPkbeRMGXucHIUL_jXrVnH_ZKXSJcv2EmPQ6KXx3rGfnz-9P3quri9-3Jz9fG2cKWoc9Fi7WrSlXC1MkohOiVlrVpXGXBQmVL2ILE2oiU0pmqx6jrV6rYrWxK9keUZe3u4O8fwe6GU7ejTlhknCkuyGoSptFIrqA6giyGlSL2dox8x3lsQdvNrH_zaTZ4VYB_82mbde318sLQjdY9bR6Er8OYIYHI49Ksq59MjVwFo1WyHLg8crTr-eIo2OU-rvM5Hctl2wf8nyl9jyJiF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71084755</pqid></control><display><type>article</type><title>High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Baynes, Roy D ; Dansey, Roger D ; Klein, Jared L ; Hamm, Caroline ; Campbell, Mark ; Abella, Esteban ; Peters, William P</creator><creatorcontrib>Baynes, Roy D ; Dansey, Roger D ; Klein, Jared L ; Hamm, Caroline ; Campbell, Mark ; Abella, Esteban ; Peters, William P</creatorcontrib><description>Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field.</description><identifier>ISSN: 0093-7754</identifier><identifier>EISSN: 1532-8708</identifier><identifier>DOI: 10.1016/S0093-7754(01)90131-9</identifier><identifier>PMID: 11498831</identifier><identifier>CODEN: SOLGAV</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Breast Neoplasms - therapy ; Clinical Trials as Topic ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Seminars in oncology, 2001-08, Vol.28 (4), p.377-388</ispartof><rights>2001</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c306t-ba6c6e740c65855aac52265bc481c14832f12a680bea884ba4dd5b7bd3be0f823</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0093-7754(01)90131-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14117599$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11498831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baynes, Roy D</creatorcontrib><creatorcontrib>Dansey, Roger D</creatorcontrib><creatorcontrib>Klein, Jared L</creatorcontrib><creatorcontrib>Hamm, Caroline</creatorcontrib><creatorcontrib>Campbell, Mark</creatorcontrib><creatorcontrib>Abella, Esteban</creatorcontrib><creatorcontrib>Peters, William P</creatorcontrib><title>High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?</title><title>Seminars in oncology</title><addtitle>Semin Oncol</addtitle><description>Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - therapy</subject><subject>Clinical Trials as Topic</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0093-7754</issn><issn>1532-8708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFu1DAQhi1ERZfCI4B8AcEhxePEsdNLhSqglSoVCThbE2fCGiVxsB2kvj1Jd0WPnEYz-mbm18fYKxDnIKD-8E2Ipiy0VtU7Ae8bASUUzRO2A1XKwmhhnrLdP-SUPU_plxAStJTP2ClA1RhTwo7Rtf-5L7qQiLs9jSHvKeJ8z3Hq-NpjDnPwlL3jKdPIHQ0DzxGnNA84Zcw-TLwPkbeRMGXucHIUL_jXrVnH_ZKXSJcv2EmPQ6KXx3rGfnz-9P3quri9-3Jz9fG2cKWoc9Fi7WrSlXC1MkohOiVlrVpXGXBQmVL2ILE2oiU0pmqx6jrV6rYrWxK9keUZe3u4O8fwe6GU7ejTlhknCkuyGoSptFIrqA6giyGlSL2dox8x3lsQdvNrH_zaTZ4VYB_82mbde318sLQjdY9bR6Er8OYIYHI49Ksq59MjVwFo1WyHLg8crTr-eIo2OU-rvM5Hctl2wf8nyl9jyJiF</recordid><startdate>200108</startdate><enddate>200108</enddate><creator>Baynes, Roy D</creator><creator>Dansey, Roger D</creator><creator>Klein, Jared L</creator><creator>Hamm, Caroline</creator><creator>Campbell, Mark</creator><creator>Abella, Esteban</creator><creator>Peters, William P</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200108</creationdate><title>High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?</title><author>Baynes, Roy D ; Dansey, Roger D ; Klein, Jared L ; Hamm, Caroline ; Campbell, Mark ; Abella, Esteban ; Peters, William P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c306t-ba6c6e740c65855aac52265bc481c14832f12a680bea884ba4dd5b7bd3be0f823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - therapy</topic><topic>Clinical Trials as Topic</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baynes, Roy D</creatorcontrib><creatorcontrib>Dansey, Roger D</creatorcontrib><creatorcontrib>Klein, Jared L</creatorcontrib><creatorcontrib>Hamm, Caroline</creatorcontrib><creatorcontrib>Campbell, Mark</creatorcontrib><creatorcontrib>Abella, Esteban</creatorcontrib><creatorcontrib>Peters, William P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baynes, Roy D</au><au>Dansey, Roger D</au><au>Klein, Jared L</au><au>Hamm, Caroline</au><au>Campbell, Mark</au><au>Abella, Esteban</au><au>Peters, William P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?</atitle><jtitle>Seminars in oncology</jtitle><addtitle>Semin Oncol</addtitle><date>2001-08</date><risdate>2001</risdate><volume>28</volume><issue>4</issue><spage>377</spage><epage>388</epage><pages>377-388</pages><issn>0093-7754</issn><eissn>1532-8708</eissn><coden>SOLGAV</coden><abstract>Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field.</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>11498831</pmid><doi>10.1016/S0093-7754(01)90131-9</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0093-7754 |
| ispartof | Seminars in oncology, 2001-08, Vol.28 (4), p.377-388 |
| issn | 0093-7754 1532-8708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71084755 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Breast Neoplasms - therapy Clinical Trials as Topic Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Female Hematopoietic Stem Cell Transplantation Humans Medical sciences Pharmacology. Drug treatments |
| title | High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A31%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-dose%20chemotherapy%20and%20hematopoietic%20stem%20cell%20transplantation%20for%20breast%20cancer:%20Past%20or%20future?&rft.jtitle=Seminars%20in%20oncology&rft.au=Baynes,%20Roy%20D&rft.date=2001-08&rft.volume=28&rft.issue=4&rft.spage=377&rft.epage=388&rft.pages=377-388&rft.issn=0093-7754&rft.eissn=1532-8708&rft.coden=SOLGAV&rft_id=info:doi/10.1016/S0093-7754(01)90131-9&rft_dat=%3Cproquest_cross%3E71084755%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71084755&rft_id=info:pmid/11498831&rft_els_id=S0093775401901319&rfr_iscdi=true |